Pipeline
Advancing novel product candidates for cardiometabolic disorders
We are in Phase 2 clinical development of three high value cardiometabolic indications.
Our lead program, ninerafaxstat, is currently in Phase 2 clinical development for conditions of oxygen deprivation in the heart. The initial indications we are targeting with ninerafaxstat are non-obstructive hypertrophic cardiomyopathy, heart failure and stable angina.
